Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 May;14(5):1299-1301.
doi: 10.21037/jtd-22-312.

Intratumoral and intertumoral heterogeneity drives EGFR treatment considerations

Kevin Lu  1 , Hatim Husain  2
Affiliations
Editorial

Intratumoral and intertumoral heterogeneity drives EGFR treatment considerations

Kevin Lu et al. J Thorac Dis. 2022 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-312/coif). HH reports consulting fees from Janssen and Astrazeneca, and honorarium from Janssen, Astrazeneca, Neogenomics and Foundation Medicine, but there are no conflicts of interest related to this work in particular. The other author has no conflicts of interest to declare.

Comment on

References

    1. Sequist LV, Neal JW. Personalized, genotype-directed therapy for advanced non-small cell lung cancer. 2021 [updated 2021; cited 2022 March 7]. Available online: https://www.uptodate.com/contents/personalizedgenotype-directed-therapy-...
    1. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018;378:113-25. 10.1056/NEJMoa1713137 - DOI - PubMed
    1. Du W, Zhao Y, Xuan Y, et al. Different efficacy in the nonsmall cell lung cancer patient with bilateral synchronous lesions treated with neoadjuvant gefitinib therapy: a case report. J Thorac Dis 2020;12:1582-7. 10.21037/jtd.2020.02.60 - DOI - PMC - PubMed
    1. Jia Z, Wang Y, Cao L, et al. First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up. J Thorac Dis 2020;12:3764-73. 10.21037/jtd-20-1882 - DOI - PMC - PubMed
    1. Aggarwal C, Thompson JC, Black TA, et al. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic NonSmall Cell Lung Cancer. JAMA Oncol 2019;5:173-80. 10.1001/jamaoncol.2018.4305 - DOI - PMC - PubMed